The table below shows Akari Therapeutics Plc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
-
-
-
-
-
$0.00
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$1.46M
$249.00K
$667.00K
$813.00K
$143.00K
$3.31M
SG&A
AKTX annual revenue (10-K history)
Akari Therapeutics Plc reported annual revenue of $367.88K for fiscal year 2023. That is down 39.5% from $607.68K in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.